Chief Medical Officer, BIND TherapeuticsBiography
Hagop Youssoufian, M.Sc., M.D., has served as BIND Therapeutic's Chief Medical Officer since November 2014 and additionally has led Regulatory Affairs and Quality Assurance activities since March 2015. Prior to joining BIND, Dr. Youssoufian served as Executive Vice President of Research and Development at Progenics Pharmaceuticals and was previously President of Research and Development and Chief Medical Officer at Ziopharm Oncology. Dr. Youssoufian has also held senior medical and R&D leadership positions at Lilly, Imclone Systems, Sanofi Aventis and Bristol-Myers Squibb. He completed fellowships in Clinical Genetics at Johns Hopkins and in Hematology-Oncology at Massachusetts General Hospital, and was a Visiting Scientist at Whitehead Institute, MIT. Dr. Youssoufian has served on the faculties at Baylor College of Medicine and Harvard Medical School and received his M.Sc. and M.D. from the University of Massachusetts Medical School and a B.S. from Boston College.